Research programme: COMT inhibitors - Cerecor

Drug Profile

Research programme: COMT inhibitors - Cerecor

Alternative Names: CERC 425; CERC-406

Latest Information Update: 09 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck & Co
  • Developer Cerecor
  • Class Small molecules
  • Mechanism of Action Catechol-O-methyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Depressive disorders

Most Recent Events

  • 02 Apr 2018 Cerecor has patent protection for COMT inhibitor compounds in Australia, Canada, China, Japan, South Korea, Mexico, and Russia, Brazil, Europe, and India
  • 23 Mar 2016 Cerecor announces intention to file an IND for CERC 406, with the US FDA (Cerecor, Form 10-K, March 2016)
  • 23 Mar 2016 Cerecor has patent protection for COMT inhibitor compounds in USA (Cerecor, Form 10-K, March 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top